We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Rapid Therapeutic Science Laboratories Inc (PK) | USOTC:RTSL | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.005 | 0.0012 | 0.0059 | 0.00 | 14:30:17 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (Date of earliest event reported):
____________________
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) | (Zip code) |
Registrant’s telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Item 4.01.Change in Registrant’s Certifying Accountant.
Effective July 12, 2023, PWR CPA, LLP (“PWR”) advised Rapid Therapeutic Science Laboratories, Inc. (the “Company”) that it had reached a decision to resign as the Company’s independent registered public accounting firm for business reasons. As a result, the Company’s Board of Directors recommended and approved the engagement of TPS Thayer, LLC (“TPS”) to serve as the Company’s independent registered public accounting firm, effective immediately.
The report of PWR on the financial statements of the Company as of and for the two years ended December 31, 2022, contained no adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope, or accounting principles.
During the Company’s two fiscal years ended December 31, 2022, and the subsequent interim period from January 1, 2023 to the date of this report, there were no disagreements between the Company and PWR on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of PWR, would have caused PWR to make reference to the subject matter of such disagreements in connection with its audit reports on the Company’s financial statements.
During the Company’s fiscal year ended December 31, 2022, and the subsequent interim period from January 1, 2023 to the date of this report, there were no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K.
During the Company’s fiscal years ended December 31, 2022 and 2021, and the subsequent interim period from January 1, 2023 to the date of this report, the Company did not consult with TPS regarding any of the matters set forth in Items 304(a)(2)(i) and (ii) of Regulation S-K.
The Company has provided PWR with a copy of the disclosures in this report and has requested that PWR furnish it with a letter containing its statements with regard to this matter. A copy of this letter is filed as Exhibit 16.1 to this report.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
The following Exhibits are filed herewith:
Exhibit No. |
| Description |
|
|
|
| Letter to the Company from PWR CPA, LLP dated July 12, 2023. | |
|
|
|
104 |
| Inline XBRL for the cover page of this Current Report on Form 8-K |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
RAPID THERAPEUTIC SCIENCE
LABORATORIES, INC.
/s/ Donal R. Schmidt, Jr.
Donal R. Schmidt, Jr.
Chief Executive Officer
July 14, 2023
3
July 12, 2023
Mr. Donal Schmidt
Chief Executive Officer
Rapid therapeutic Science
558 County Road 472
De Leon, Texas 76444
Dear Mr. Schmidt,
We hereby resign as principal auditor for Rapid Therapeutic Science Laboratories, Inc, (The Company) effective the date of this letter of notice.
This is also to confirm that the client-auditor relationship between Rapid Therapeutic Science Laboratories, Inc. (Commission File Number 000-55018) and PWR CPA, LLP has ceased.
Sincerely,
/s/ PWR CPA, LLP
PWR CPA, LLP
cc:Office of the Chief Accountant
SECPS Letter File
Securities and Exchange Commission
SECPSletters@sec.gov
Document and Entity Information |
Jul. 12, 2023 |
---|---|
Details | |
Registrant CIK | 0001575659 |
Document Type | 8-K |
Document Period End Date | Jul. 12, 2023 |
Entity Registrant Name | Rapid Therapeutic Science Laboratories, Inc. |
Entity Incorporation, State or Country Code | NV |
Entity File Number | 001-55018 |
Entity Tax Identification Number | 46-2111820 |
Entity Address, Address Line One | 558 County Road 472 |
Entity Address, City or Town | De Leon |
Entity Address, State or Province | TX |
Entity Address, Postal Zip Code | 76444 |
City Area Code | 800 |
Local Phone Number | 497-6059 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
Amendment Flag | false |
1 Year Rapid Therapeutic Scienc... (PK) Chart |
1 Month Rapid Therapeutic Scienc... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions